Eli Lilly’s actions increased by 15% after a clinical trial of their experimental pill showed that it helped patients with type 2 diabetes to lose weight at levels comparable to the main injectable medications such as Ozempic.
The results of the mid -stage trial announced in Thorsday by the pharmaceutical giant showed that patients taking Orforgerlipro lost an average of 16 pounds, or 7.9% of their body weight, a 26 -week period.
This result is favorably compared with the widely prescribed Ozempic of Novo Nordisk, which helped diabetic patients lose about 6% of their body weight in their highest approved dose.
Lilly’s shares recently increased 14% to $ 838.80 in Thursday’s negotiation.
“This represents an important potential advance for patients looking for an option without needles for weight and glucose management,” Eli Lilly said in a statement on Thursday.
The medicine also reduced the blood sugar levels of patients by 1.3% on average.
While this reduction was slightly below the 2.1% drop seen with Ozempic, the general effectiveness of orforglipron in the loss of promotion weight and diabetes control has been enthusiastically.
Meanwhile, the actions of the Danish company Novo Nordisk, which markets both Ozempic and the highest dose weight loss variant, slipped 3.9% in the midst that an viable oral competitor could market domain.
Orforglipron belongs to the same kind of drugs as Ozempic and Wogovy, known as GLP-1 receiver agonists.
These medications mimic a hormone called the Glucagon-like peptide, which regulates appetite, insulin secretion and blood sugar.
Although it was originally developed to treat type 2 diabetes, GLP-1 medications have increased in popularity due to their ability to boost a substantial weight loss.
The demand for thesis thesis has shot in recent years, since continuous obesity rates to rise worldwide and patients see more and more pharmaceutical solutions for weight control.
One of the main barriers for the broader adoption of current LPG-1 therapies, such as Ozempic and Wogovy, has been its injectable form.
That has made the development of oral alternatives a priority for drug manufacturers.
If approved, Eli Lilly’s orforgripron could remodel the landscape by offering a more convenient approach based on pills with comparable effectiveness.
The Orforglipron essay is one of the various studies that Lilly is doing to evaluate the potential variety of the medication, a variety of conditions, including obesity and sleep apnea.
According to the registration of clinical trials of the US government, the main obesity test of Lilly is not expected to end until at least July.
If the data is still favorable, the company expects to request a regulatory approach at the beginning of 2026, said the CEO of Lilly, David Ricks, to Bloomberg Television earlier this year.
The news comes in the midst of recent setbacks in the oral space LPG-1.
Pfizer stopped the development of one of its candidates for the obesity pill at the end of 2023, citing tolerigity situations.
Novo Nordisk has also faced questions about the durability and consistency of the results of its own oral formulations.